Search for European Projects

19 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy (NoCanTher)

Start date: Apr 1, 2016, End date: Mar 31, 2021,

During the last four years the Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by ...
Read Project

 13

 FINISHED 

A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients (MERCURIC)

Start date: Dec 1, 2013, End date: Nov 30, 2020,

Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omi ...
Read Project

 13

 FINISHED 

Deciphering PI3K biology in health and disease (Phd)

Start date: Nov 1, 2015, End date: Oct 31, 2019,

The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of the PI3K signalling pathway in a number of different diseases, ranging from inflammation and diabetes to cancer, with PI3K pathway alterations present in almost 80% of hu ...
Read Project

 11

 FINISHED 

Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) (MoTriColor)

Start date: Oct 1, 2015, End date: Sep 30, 2019,

Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different.We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assa ...
Read Project

 12

 FINISHED 

Therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway in mismatch repair deficient hypermutant tumors (Wnt and CRC)

Start date: Sep 1, 2017, End date: Aug 31, 2019,

Colorectal cancer (CRC) is a leading cause of death worldwide. Mutations in components of the canonical Wnt/beta-catenin pathway such as APC, CTNNB1/beta-catenin, AXIN2 and more recently RNF43 or ZNRF3 can contribute to CRC tumorigenesis. The hosting team and Dr. Clevers’ group have recently described that inhibitors of the porcupine enzyme, that is essential for the maturation of Wnt-ligands, hav ...
Read Project

 2

 FINISHED 

Pushing Myc inhibition towards the clinic (Mycinhibinclinic)

Start date: May 1, 2014, End date: Apr 30, 2019,

Deregulation of the Myc oncogene promotes tumorigenesis in most if not all cancers and is often associated with poor prognosis. However, targeting Myc has long been considered impossible because of potential catastrophic side effects in normal tissues. Despite this general assumption, we showed that Myc inhibition displays extraordinary therapeutic benefit in various transgenic mouse models of can ...
Read Project

 2

 FINISHED 

Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities (MedBioinformatics) (MedBioinformatics)

Start date: May 1, 2015, End date: Apr 30, 2018,

Progress in biomedical research and healthcare requires profiting from the huge amount of data and knowledge that are generated. However, most of the potential users have no means to efficiently exploit this wealth of information. Up to now, many of the efforts done for developing bioinformatics methods and applications have not produced the expected societal impact for different reasons, includin ...
Read Project

 13

 FINISHED 

Developing an anti-Myc cell-penetrating peptide for cancer treatment (GBM-CPP)

Start date: Aug 1, 2016, End date: Jul 31, 2017,

Despite ever-increasing investments in the development of new treatments, many cancers remain incurable. One reason is that most current therapies target redundant functions around which tumour cells can build resistance. We focus instead on a unique and essential cellular function: the Myc oncogene, deregulated in more than 70% of human cancers. Targeting Myc has long been considered unfeasible b ...
Read Project

 2

 FINISHED 

Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)

Start date: Jan 1, 2011, End date: Dec 31, 2016,

"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Read Project

 8

 FINISHED 

Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system. (CSC-IS)

Start date: Jul 1, 2015, End date: Dec 31, 2016,

Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, ...
Read Project

 2

 FINISHED 

A European Platform for Translational Cancer Research (EUROCANPLATFORM)

Start date: Jan 1, 2011, End date: Dec 31, 2016,

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Read Project

 29

 FINISHED 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Start date: Jan 1, 2011, End date: Dec 31, 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Read Project

 22

 FINISHED 

WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients (WINTHER)

Start date: Mar 1, 2013, End date: Feb 28, 2015,

Relevance: WINTHER project focuses on the development and validation, in 24 months, of industry supported new tools and computational methods, to predict efficacy of drugs in cancer patientsCurrent medical needs: Selection of cancer targeted therapies based on molecular abnormalities (mutations /amplifications/ translocations) benefit today only to 10-40% of patients. For the remaining majority, ...
Read Project

 12

 FINISHED 

Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)

Start date: Jan 1, 2011, End date: Dec 31, 2014,

Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Read Project

 11

 FINISHED 

OVErcoming Resistance to anti-HER2 therapy (OVER-HER2)

Start date: Jan 1, 2011, End date: Dec 31, 2014,

"HER2 is a membrane receptor tyrosine kinase overexpressed in 30% of breast tumors and results in an aggressive clinical course. Anti-HER2 therapies including monoclonal antibodies (trastuzumab) and small-molecule tyrosine kinase inhibitors (lapatinib) are active and have improved survival of patients with HER2 overexpressing breast cancer. However, the emergence of primary or acquired resistance ...
Read Project

 2

 FINISHED 

Role of Notch signaling pathway in Glioma Stem Cells (Notch pathway in GSC)

Start date: Jun 1, 2012, End date: Sep 20, 2014,

Glioblastoma multiforme (GBM) is the most common malignant intracranial tumor in adults. Despite the knowledge of the genetic alterations associated to GBM and the improvement in neurosurgery and chemo- and radiotherapy, little improvement has been achieved in the median survival. Recently, glioma stem cells (GSCs) have been identified to be responsible of the origin, recurrence and drug resistanc ...
Read Project

 2

 FINISHED 

Molecular Mechanisms of Glioma Genesis and Progression (Glioma)

Start date: Aug 1, 2008, End date: Jul 31, 2014,

Glioma is the most common and aggressive tumour of the brain and its most malignant form, glioblastoma multiforme, is nowadays virtually not curable. Very little is known about glioma genesis and progression at the molecular level and not much progress has been achieved in the treatment of this disease during the last years. The understanding of the molecular mechanisms involved in the biology of ...
Read Project

 3

 FINISHED 

Pathway-based Secretomes in Breast Cancer Biomarker Discovery (PathSec-BCa-BM)

Start date: May 1, 2010, End date: Apr 30, 2014,

Improvements in the characterization of human tumors have resulted in better survival rates for cancer patients. However, less progress has been made in the development of clinical tools to monitor the course of the disease. Tumor markers have not had a broad acceptance in the clinical community, because the few that are known are organ rather than tumor specific. Proteomics biomarker discovery re ...
Read Project

 2

 FINISHED 

Targeting Cancer Stem Cells (CSC) for the development of more effective treatments to cure cancer patients (Anti-CSC)

Start date: Dec 1, 2012, End date: Nov 30, 2013,

Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, ...
Read Project

 2